Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Markets for Erectile Dysfunction Drugs

This article was originally published in Start Up

Executive Summary

Three drugs for erectile dysfunction (ED) accounted for sales of $3.1 billion in 2007, according to "European Markets for Erectile Dysfunction Drugs, Devices, and Therapies," a recent report from Medtech Insight. But the European market remained largely underpenetrated in 2007, creating a great business opportunity for some of the smaller specialty pharma and urology-focused device firms focused on ED.

You may also be interested in...



Jumpstart Pays Faster than Discovery: The Moral of the TransForm/J&J Acquisition

With its acquisition of TransForm, J&J has cemented its position as the Big Pharma most interested in the power of jumpstart strategies to create new drugs. The new deal is dwarfed by J&J's 2001 acquisition of Alza, but philosophically the two deals are very much the same--platform technologies that quickly generate relatively low-risk product opportunities for J&J.

Jumpstart to Products

Discovery research is an ever more difficult investment to justify, so companies are placing greater emphasis on mining discoveries that have already been made but whose real value remains unexploited. Big Pharma, in part inhibited by habit and current infrastructure, has not moved aggressively in the new direction-but the jumpstart model now dominates small-company strategies and will increasingly translate into the rest of the industry.

American Medical Systems' Make Over

The sale of American Medical Systems to private equity investor Warburg Pincus started the company on a new path. Long successful in male-focused markets like erectile dysfunction, part of the new direction for AMS entailed a new management team and a reinvigorated product development effort. But in AMS's case, the development effort was focused not on the company's core business, but in a related area, products to treat female uro-genital problems. Though similar in some respects, the urology and gynecology markets are more notable for their striking differences. AMS's male-oriented lines are market development-driven, aimed at educating and attracting customers among men reluctant to seek care; gynecology is more about product development, getting new therapies into the hands of patients eager to use them.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel